Compounds > indazoles

Page last updated: 2024-08-21

indazoles and veliparib

indazoles has been researched along with veliparib in 12 studies

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	8 (66.67)	24.3611
2020's	4 (33.33)	2.80

Authors

Authors	Studies
Konstantinopoulos, PA; Liu, JF; Matulonis, UA	1
Chen, CS; de Necochea-Campion, R; Duerksen-Hughes, PJ; Ferris, RL; Hsu, HW; Mirshahidi, S; Simental, AA; Williams, V	1
Matsumoto, K; Onda, T; Yaegashi, N	1
DiGiammarino, EL; Donawho, CK; Gao, W; Hopkins, TA; Johnson, EF; Maag, D; Olson, AM; Osterling, DJ; Panchal, SC; Rodriguez, LE; Shi, Y; Solomon, LR; Stolarik, DF; Wilsbacher, JL	1
Seimiya, H	1
Agnihotri, S; Buczkowicz, P; Chornenkyy, Y; Dirks, PB; Garzia, L; Golbourn, B; Hawkins, C; Leung, S; Rakopoulos, P; Rutka, JT; Siddaway, R; Taylor, MD; Yu, M	1
Cohen, MS; Ekblad, T; Karlberg, T; Löw, M; Moche, M; Pinto, AF; Schüler, H; Thorsell, AG; Trésaugues, L	1
Coleman, RL; Kurnit, KC; Westin, SN	1
Cui, M; Han, L; Wang, L; Wang, Q; Xu, Y	1
Rodrigues, M	1
Luger, K; Roberts, G; Rudolph, J	1
Artali, R; Aviñó, A; Dallavalle, S; Eritja, R; Gargallo, R; Mattio, LM; Mazzini, S; Musso, L; Pisano, C; Princiotto, S	1

Reviews

5 review(s) available for indazoles and veliparib

Article	Year
PARP inhibitors in ovarian cancer: current status and future promise. Gynecologic oncology, 2014, Volume: 133, Issue:2 Topics: Antineoplastic Agents; Benzimidazoles; DNA Repair; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2014
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives. Japanese journal of clinical oncology, 2015, Volume: 45, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids	2015
[Cancer therapy by PARP inhibitors]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8 Topics: Antineoplastic Agents; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; DNA Breaks, Double-Stranded; DNA Replication; DNA, Single-Stranded; Enzyme Inhibitors; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Mutation; Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Recombinational DNA Repair	2015
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. Current treatment options in oncology, 2018, 11-15, Volume: 19, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carbazoles; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Phthalazines; Phthalimides; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2018
Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance. Current drug targets, 2020, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; DNA Repair; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases	2020

Other Studies

7 other study(ies) available for indazoles and veliparib

Article	Year
Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells. Oral oncology, 2014, Volume: 50, Issue:7 Topics: Apoptosis; Benzimidazoles; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; DNA Breaks; Head and Neck Neoplasms; Histones; Humans; Indazoles; Phenylurea Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rad51 Recombinase	2014
Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors. Molecular cancer research : MCR, 2015, Volume: 13, Issue:11 Topics: Animals; Antineoplastic Agents, Alkylating; Benzimidazoles; Cell Line; Cell Line, Tumor; DNA Damage; DNA Repair; DNA-Binding Proteins; Drug Tolerance; Humans; Indazoles; Mice; Neoplasms, Experimental; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases	2015
Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma. Molecular cancer therapeutics, 2015, Volume: 14, Issue:11 Topics: Animals; Astrocytoma; Benzimidazoles; Blotting, Western; Brain Stem Neoplasms; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Child; Combined Modality Therapy; Glioma; Humans; Indazoles; Kaplan-Meier Estimate; Linear Models; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Microscopy, Confocal; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Pons; Radiotherapy; Xenograft Model Antitumor Assays	2015
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. Journal of medicinal chemistry, 2017, 02-23, Volume: 60, Issue:4 Topics: Animals; Benzimidazoles; Enzyme Inhibitors; HEK293 Cells; Humans; Indazoles; Models, Molecular; Phenanthrenes; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Tankyrases	2017
[PARP inhibitors in first-line of ovarian cancers]. Bulletin du cancer, 2020, Volume: 107, Issue:1 Topics: Benzimidazoles; Clinical Trials as Topic; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Phenotype; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors	2020
Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs. Nature communications, 2021, 02-02, Volume: 12, Issue:1 Topics: Antineoplastic Agents; Benzamides; Benzimidazoles; Binding Sites; Carrier Proteins; Catalysis; Catalytic Domain; DNA Repair Enzymes; Humans; Indazoles; Indoles; Nuclear Proteins; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Protein Binding	2021
Investigation of the Complexes Formed between PARP1 Inhibitors and PARP1 G-Quadruplex at the Gene Promoter Region. International journal of molecular sciences, 2021, Aug-14, Volume: 22, Issue:16 Topics: Benzimidazoles; DNA; G-Quadruplexes; Humans; Indazoles; Magnetic Resonance Spectroscopy; Models, Molecular; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Promoter Regions, Genetic	2021